ASSOCIATIONS D'INHIBITEURS DE RET ET D'INHIBITEURS DE MTORC1, ET UTILISATIONS DE CELLES-CI POUR LE TRAITEMENT DE CANCERS LIÉS À UNE ACTIVITÉ RET ABERRANTE

• 收藏
• 分享

专利权人:

Blueprint Medicines Corporation

发明人:

申请号：

EP18730519.8

公开号：

EP3624802A1

申请日:

2018.05.15

申请国别(地区):

EP

年份:

2020

代理人:

摘要：

This disclosure relates to combinations of RET inhibitors and inhibitors of mTORC1 and their use in the treatment of various cancers mediated by aberrant RET activity. Preferably, the cancer is chosen from thyroid cancer, non-small cell lung cancer, paraganglioma or intrahepatic bile duct carcinoma. The RET inhibitor preferably is BLU-667, and the mTORC1 inhibitor preferably is everolimus or AZD8055.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/